X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Aurobindo Pharma Fact Sheet, Aurobindo Pharma Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Aurobindo Pharma Fact Sheet   (AUBD)

Here is the latest financial fact sheet of Aurobindo Pharma. For more details, see the Aurobindo Pharma quarterly results and Aurobindo Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

AUROBINDO PHARMA Price History

Price Rs 673.0
Mkt Cap Rs m 393,819
Vol '000 135.1
P/E X 17.2
P/CF X 16.6
EPS (TTM) Rs 39.2
% ch % 0.4
No. of shares m 585.17
% ch week % 2.7
% ch 1-mth % 31.0
% ch 12-mth % -7.8
52 week H/L Rs 895.0/504.0
(As on Jun 29, 2017 03:36:00 PM)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

AUROBINDO PHARMA Financials

No. of Mths
Year Ending
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
5-Yr Chart
Click to enlarge
AUROBINDO PHARMA EQUITY SHARE DATA
High Rs2062055451,2801,541 
Low Rs80100139509582 
Sales per share (Unadj.) Rs159.0201.1277.9415.1237.5 
Earnings per share (Unadj.) Rs-4.210.140.254.033.9 
Diluted earnings per shareRs-2.15.020.026.933.9 
Cash flow per share (Unadj.) Rs2.618.651.065.440.6 
Dividends per share (Unadj.) Rs1.001.503.004.502.50 
Adj. dividends per shareRs0.500.751.492.252.50 
Dividend yield (eoy) %0.71.00.90.50.2 
Book value per share (Unadj.) Rs80.489.5128.7176.6120.6 
Adj. book value per shareRs40.044.564.188.1120.6 
Shares outstanding (eoy) m291.12291.21291.46291.98585.17 
Bonus/Rights/Conversions  ----PREF 
Price / Sales ratio x0.90.81.22.24.5 
Avg P/E ratio x-33.715.18.516.631.3 
P/CF ratio (eoy) x54.08.26.713.726.2 
Price / Book Value ratio x1.81.72.75.18.8 
Dividend payout %-23.614.97.58.37.4 
Avg Mkt Cap Rs m41,63044,35199,577261,147621,041 
No. of employees `0008.68.89.511.613.3 
Total wages/salary Rs m5,3576,6338,02413,02315,508 
Avg. sales/employee Rs Th5,358.96,653.88,526.110,469.510,457.6 
Avg. wages/employee Rs Th620.4753.8844.71,124.91,167.1 
Avg. net profit/employee Rs Th-143.0333.91,234.61,361.11,491.6 
AUROBINDO PHARMA INCOME DATA
Net Sales Rs m46,27458,55380,998121,205138,961 
Other income Rs m2472852169671,663 
Total revenues Rs m46,52158,83981,214122,172140,624 
Gross profit Rs m5,6138,61021,33725,63632,056 
Depreciation Rs m2,0052,4873,1253,3263,926 
Interest Rs m2,7722,6663,1021,5992,568 
Profit before tax Rs m1,0823,74115,32521,67927,225 
Minority Interest Rs m625384539 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m-3,2120000 
Tax Rs m-8888273,6355,9667,444 
Profit after tax Rs m-1,2352,93911,72915,75819,820 
Gross profit margin %12.114.726.321.223.1 
Effective tax rate %-82.122.123.727.527.3 
Net profit margin %-2.75.014.513.014.3 
AUROBINDO PHARMA BALANCE SHEET DATA
Current assets Rs m32,64041,36856,31282,988100,015 
Current liabilities Rs m29,15134,30842,20061,36474,759 
Net working cap to sales %7.512.117.417.818.2 
Current ratio x1.11.21.31.41.3 
Inventory Days Days122120107109107 
Debtors Days Days98100119107110 
Net fixed assets Rs m28,40128,57427,36641,09852,350 
Share capital Rs m291291292292585 
"Free" reserves Rs m22,62425,06235,80249,86767,707 
Net worth Rs m23,39726,05837,50251,55970,567 
Long term debt Rs m9,64611,48312,79413,6158,472 
Total assets Rs m62,37672,77894,898129,145156,994 
Interest coverage x1.42.45.914.611.6 
Debt to equity ratio x0.40.40.30.30.1 
Sales to assets ratio x0.70.80.90.90.9 
Return on assets %2.57.715.613.414.3 
Return on equity %-5.311.331.330.628.1 
Return on capital %2.017.136.735.837.7 
Exports to sales %63.266.165.851.651.0 
Imports to sales %31.831.226.719.218.8 
Exports (fob) Rs m29,24038,71053,26962,51470,927 
Imports (cif) Rs m14,69918,27921,60723,27226,193 
Fx inflow Rs m29,78039,05653,42062,61371,015 
Fx outflow Rs m18,31219,44623,25125,32928,799 
Net fx Rs m11,46819,61030,16937,28442,216 
AUROBINDO PHARMA CASH FLOW
From Operations Rs m 3,263 2,749 6,463 12,368 17,596 
From Investments Rs m -5,632 -2,463 -8,187 -13,980 -13,801 
From Financial Activity Rs m 1,189 1,081 1,176 932 -198 
Net Cashflow Rs m -1,181 1,366 -548 -680 3,597 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 54.1%
Foreign collaborators 0.0%
Indian inst/Mut Fund 8.0%
FIIs 27.7%
ADR/GDR 0.0%
Free float 10.2%
Shareholders 69,601
Pledged promoter(s) holding 8.6%
 

Company Information

REGD OFF Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038
E-MAIL cs@aurobindo.com WEB www.aurobindo.com
TELEPHONE (040) 6672 5333 FAX (040) 2374 1080
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Karvy Computershare, 17-24, Vithalrao Nagar, Madhapur, Hyderabad-81
AUDITOR S. R. Batliboi & Assoc.
CHM: K. Ragunathan COMP SEC: A. Mohan Rami Reddy YEAR OF INC: 1986 BSE CODE: 524804 FV (Rs): 1 DIV YIELD (%): 0.4

More Pharmaceuticals Company Fact Sheets:   STRIDES SHASUN LTD  PIRAMAL ENTERPRISES  IPCA LABS  UNICHEM LAB  PANACEA BIOTECH  

Compare AUROBINDO PHARMA With:   STRIDES SHASUN LTD  PIRAMAL ENTERPRISES  IPCA LABS  UNICHEM LAB  PANACEA BIOTECH  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trims Early Gains to Finish Flat; Indigo Slips 2.3%(Closing)

Indian share markets trimmed its early gains in the afternoon session to finish just above the dotted line amid mixed global cues.

Views on news

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

More Views on News

Most Popular

The 'Multibagger IPOs' You Should Be Betting On(The 5 Minute Wrapup)

Jun 22, 2017

Multibagger IPOs are few and far between. Here's how to spot them...

After Farm Loans, Will Govts Waive Off Mudra Loans Next?(Vivek Kaul's Diary)

Jun 19, 2017

If borrowers organise themselves and ask the government to waive off their loans, the government will find it very difficult to say no, having already established a precedent.

Get Ready for Commodity Options!(Daily Profit Hunter)

Jun 16, 2017

Commodity options trading is one step closer to reality. Learn how to take advantage of this tremendous opportunity.

Walter Schloss' Investing Record(Chart Of The Day)

Jun 17, 2017

In a market full of one-hit-wonders, this investor obviously had a formula that worked. And through the think-and-thin of the market.

11 Hidden Costs Associated With Your Home Loan(Outside View)

Jun 16, 2017

Various costs associated with a home loan.

More

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - PLETHICO PHARMA COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS